StreetAlpha.app
Home › Stocks › ANIX

Anixa Biosciences Inc (ANIX)

$2.44
▼ −6.15%
LAST CLOSE · NOV 20

Anixa Biosciences develops cancer therapies and vaccines, mainly for ovarian and breast cancer, and is based in San Jose, California. It last closed at $2.44 on Nov 20, down 6.15% on the day. For the quarter ended Jul 2026, ANIX reported EPS of -$0.08. Over the last 12 months ANIX insiders bought $522K of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is ANIX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ANIX.

Key Stats

Last 12 months
Results
Net income
−$10.4M
EPS (diluted)
−$0.32
Valuation
Market cap
$84.8M
34.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.4M
At Jul 31
Shareholder equity
$14.5M
Shares outstanding
34.8M
At Sep 9
Fiscal year endsOctober
ExchangeNasdaq
Financials history
FY2021: −$13.0M−$13.0MFY2021FY2022: −$13.6M−$13.6MFY2022FY2023: −$9.8M−$9.8MFY2023FY2024: −$12.6M−$12.6MFY2024FY2025: −$10.9M−$10.9MFY2025

From ANIX's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.08
Quarter ended Jul 2026
Year ago EPS
-$0.07
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Oct 2024: -$0.09Oct '24Jan 2025: -$0.10Jan '25Apr 2025: -$0.09Apr '25Jul 2025: -$0.07Jul '25Oct 2025: -$0.09Oct '25Jan 2026: -$0.08Jan '26Apr 2026: -$0.07Apr '26Jul 2026: -$0.08Jul '26Latest -$0.08
Revenue by quarter
Not enough quarters on file yet.
StreetAlpha's call on ANIXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ANIX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ANIX

Technical Analysis

ANIX · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 20% below its 20 day and 17% below its 50 day average. It is 21% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $2.36, and the nearest resistance the Pivot at $2.48.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 8.3%/day
Key levels
$5.4652 week high+123.8%
$3.09100 day average+26.6%
$2.95200 day average+20.9%
$2.9420 day average+20.5%
$2.8550 day average+16.8%
$2.82Swing high (Sep 21)+15.6%
$2.55Pivot R1+4.5%
$2.48Pivot+1.6%
$2.44Last close
$2.36Pivot S1−3.3%
$2.35Swing low (Jun 26)−3.7%
$2.3252 week low−4.9%
Indicators
RSI (14)36.54Weak, oversold below 30Neutral
MACD-0.10Below its signal lineBearish
Stochastic11.8Near the bottom of its rangeOversold
ADX (14)20.4Weak trend
Williams %R-95.7Oversold below −80, overbought above −20Oversold
CCI (20)-136.8Oversold below −100, overbought above 100Oversold
Rate of change−23.1%Change over 10 sessionsBearish
ATR (14)$0.20Typical daily range, 8.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANIX

What happened before

See how ANIX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ANIX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ANIX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ANIXHow many large options trades hit ANIX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ANIX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲34 buying vs 13 selling
  • ▲Held by funds +3.0 pts
  • ▲Funds holding +11
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7564+17.2%
In funds' top 1000–
Held by funds18.4%15.4%+3.0 pts
New / increased14 / 2011 / 16+25.9%
Reduced / sold out9 / 47 / 7−7.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ANIX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ANIX Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$522K21 buys · 4 insiders
Sold$00 sales · 0 insiders
Cluster buy: 2 insiders bought $61K between Oct 22 and Oct 30.
2026-01 bought $30K2026-06 bought $60K2026-07 bought $140K2026-09 bought $230K2026-10 bought $61KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 30Amit KumarCEOBuy5,000$3.17$16K
Oct 23Lewis H Titterton jrDirectorBuy8,000$2.98$24K
Oct 22Amit KumarCEOBuy8,000$2.72$22K
Sep 30Michael CatelaniPresident, COO, & CFOBuy5,500$2.84$16K
Sep 24Arnold M BaskiesDirectorBuy5,000$2.76$14K
Sep 24Amit KumarCEOBuy7,000$2.78$19K
Every insider buy and sale for ANIX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ANIX insider trades →

From SEC Form 4 filings by ANIX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANIX is in one of them and how their past ANIX trades turned out.

ANIX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ANIX in an article yet. Here's the latest on the wider market.

About Anixa Biosciences

Anixa Biosciences is a biotechnology company based in San Jose, California, that is developing cancer therapies and vaccines. Its main programs focus on ovarian cancer and breast cancer, including a cell therapy designed to treat ovarian cancer and a vaccine aimed at preventing and treating breast cancer. Its products are still being tested in clinical trials and are not yet available for sale.

Headquarters
San Jose, CA